Publication:
Cell Lineage Infidelity in PDAC Progression and Therapy Resistance.

dc.contributor.authorMalinova, Antonia
dc.contributor.authorVeghini, Lisa
dc.contributor.authorReal Arribas, Francisco
dc.contributor.authorCorbo, Vincenzo
dc.contributor.funderAssociazione Italiana Ricerca sul Cancroes_ES
dc.contributor.funderMarie Curie
dc.contributor.funderMinisterio de Ciencia y Universidades (España)
dc.date.accessioned2024-02-19T09:14:02Z
dc.date.available2024-02-19T09:14:02Z
dc.date.issued2021
dc.description.abstractInfidelity to cell fate occurs when differentiated cells lose their original identity and either revert to a more multipotent state or transdifferentiate into a different cell type, either within the same embryonic lineage or in an entirely different one. Whilst in certain circumstances, such as in wound repair, this process is beneficial, it can be hijacked by cancer cells to drive disease initiation and progression. Cell phenotype switching has been shown to also serve as a mechanism of drug resistance in some epithelial cancers. In pancreatic ductal adenocarcinoma (PDAC), the role of lineage infidelity and phenotype switching is still unclear. Two consensus molecular subtypes of PDAC have been proposed that mainly reflect the existence of cell lineages with different degrees of fidelity to pancreatic endodermal precursors. Indeed, the classical subtype of PDAC is characterised by the expression of endodermal lineage specifying transcription factors, while the more aggressive basal-like/squamous subtype is defined by epigenetic downregulation of endodermal genes and alterations in chromatin modifiers. Here, we summarise the current knowledge of mechanisms (genetic and epigenetic) of cell fate switching in PDAC and discuss how pancreatic organoids might help increase our understanding of both cell-intrinsic and cell-extrinsic factors governing lineage infidelity during the distinct phases of PDAC evolution.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipVC is supported by the Associazione Italiana Ricerca sul Cancro (AIRC; Grant No. 18178). VC and AM are also supported by the Marie Skłodowska-Curie Actions project PRECODE (Grant No:861196). Work in the laboratory of FXR is supported, in part, by Grant RTI2018-101071-B-I00 from Ministerio de Ciencia,Innovación y Universidades (Madrid, Spain) (co-funded by the ERDF-EUes_ES
dc.format.page795251es_ES
dc.format.volume9es_ES
dc.identifier.citationFront Cell Dev Biol . 2021 :9:795251.es_ES
dc.identifier.doi10.3389/fcell.2021.795251es_ES
dc.identifier.issn2296-634Xes_ES
dc.identifier.journalFrontiers in cell and developmental biologyes_ES
dc.identifier.pubmedID34926472es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/18212
dc.language.isoenges_ES
dc.publisherFrontiers Media
dc.relation.publisherversionhttps://doi.org/10.3389/fcell.2021.795251.es_ES
dc.repisalud.institucionCNIOes_ES
dc.repisalud.orgCNIOCNIO::Grupos de investigación::Grupo de Carcinogénesis Epiteliales_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleCell Lineage Infidelity in PDAC Progression and Therapy Resistance.es_ES
dc.typejournal articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublication62d13a40-e75d-49b1-bb0a-f54a4146ad3e
relation.isAuthorOfPublication.latestForDiscovery62d13a40-e75d-49b1-bb0a-f54a4146ad3e
relation.isFunderOfPublication73586a46-a526-46a7-92a9-a1e04c95faa0
relation.isFunderOfPublication6544a51b-1e06-4f2b-a7ec-42488cd60223
relation.isFunderOfPublication.latestForDiscovery73586a46-a526-46a7-92a9-a1e04c95faa0
relation.isPublisherOfPublication9f9fa5ea-093b-43d8-bf2c-5bd65d08a802
relation.isPublisherOfPublication.latestForDiscovery9f9fa5ea-093b-43d8-bf2c-5bd65d08a802

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
celllineageinfidelity_2021.pdf
Size:
1.93 MB
Format:
Adobe Portable Document Format
Description:
Artículo principal